ArsenalBio has picked up $85m in funding to commercialise immunotherapy engineering research resulting from a collaboration that includes PICI and UCSF.

Corelight, a network cybersecurity platform developer based on UC Berkeley technology, will use the cash to accelerate product development, research, sales and marketing.

Jackson Laboratory cancer drug spinout Cyteir Therapeutics extended its series B round thanks to investors including Osage University Partners and Novo Holdings.

Atomico has led $56m series B round for Cambridge-allied rare disease therapy developer Healx, which also welcomed Intel Capital as a new shareholder.

GV has contributed to a $92m series B for Tenaya, three years after it was spun out of Gladstone Institutes and University of Texas Southwestern Medical Center.

Icosavax has launched out of University of Washington with $51m in series A funding to move a vaccine for respiratory syncytial virus into a phase 1b trial.

EPFL spinout Kandou has pushed its total funding to $96m following a series C round that featured Swisscom Ventures and its Digital Transformation Fund.

Novartis and Novo helped provide $40m for the EPFL spinout that supported its acquisition of joint venture Kanyos Bio.

The telecommunications spectrum provider has now raised $120m altogether, SBA Communications and American Tower contributing to its latest round.

Gyroscope Therapeutics, a dry AMD treatment developer exploiting University of Cambridge research, has secured $61.2m from cornerstone investors Cambridge Innovation Capital and Syncona.